For those who live with diabetes, the costs of essential medications, like insulin, shouldn’t add to their burden. That’s why Cigna will offer the Patient Assurance Program beginning in 2020. By working with pharmaceutical manufacturers for this program, we will assist customers with diabetes in participating plans to manage their costs for eligible insulin products.
The Patient Assurance Program will:
A full list of drugs eligible under the program will be announced later in 2019. It will include some insulin products on the market such as Humulin, Humalog, Novolin, Novolog, and Lantus.
Beginning in early 2020, Cigna Pharmacy clients may elect to enroll in the Patient Assurance Program, upon renewal or plan start. Clients must also be upgraded to our new claims engine. Note: This program is not available to Medicare or Medicaid plans and may not be available with insured plans in all states.
The Patient Assurance Program is a blueprint for other therapeutic areas where customers may be exposed to higher out-of-pocket medication costs - which may affect adherence for some customers.2
Learn more here.
Patient Assurance Program is a trademark of Express Scripts Strategic Development, Inc.